Sequana Medical to Sponsor Liver Connect, 5 th Annual Conference of Chronic Liver Disease Foundation Ghent, Belgium – 20 March 2025 – Sequana ...

About alfapump in recurrent or refractory ascites due to liver cirrhosis & the ... primarily driven by the increasing prevalence of NASH / MASH1. The total market opportunity for alfapump is ...

The US market of recurrent and refractory ascites due to liver cirrhosis is ... primarily driven by the increasing prevalence of NASH / MASH 1. The total market opportunity for alfapump is ...

The Company estimates there are approximately 70,000 patients in the US with recurrent or refractory ascites ... primarily driven by NASH/MASH and alcoholic liver disease 1.

The main outcome measure in MAESTRO-NASH OUTCOMES (NCT05500222) is a composite end point including any event of all-cause mortality, liver transplant, ascites, hepatic encephalopathy ...

Otherwise, it would lead to diseases like acute (sudden) hepatitis (inflammation), chronic (long duration) hepatitis, fatty ...

Possible symptoms of NASH and cirrhosis, or severe scarring, include: Itchy skin, abdominal swelling, also called ascites (uh-SY-teez), shortness of breath, swelling of the legs, spider-like blood ...

Identify the warning signs of hepatitis before they become serious. From subtle fatigue to more obvious symptoms, recognizing liver inflammation early can save.

A substantial portion of compensated MASH cirrhosis patients also suffer from portal hypertension, which often leads to life threatening complications such as hepatic encephalopathy, ascites ...

The dual primary endpoints of the study will be NASH resolution and fibrosis improvement ... the complications of cirrhosis such as encephalopathy, ascites, variceal bleeding that this is reversible.